Evidence map›Paper›PMID 41705810›Full record

ReviewJournal of virology2026

Viral genome editing methods and applications in the CRISPR era.

Kihye Shin, Eui Tae Kim

Abstract readReview
In one paragraph

Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A comprehensive method for quantifying human cytomegalovirus plaque assays.Frontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kihye ShinDepartment of Microbiology and Immunology, Jeju National University College of Medicine, Jeju, Republic of Korea.ORCID 0000-0001-8044-4530
Eui Tae KimDepartment of Microbiology and Immunology, Jeju National University College of Medicine, Jeju, Republic of Korea.ORCID 0000-0002-1631-3197

Funding

Korea Health Industry Development Institute RS-2025-02223595Korea Health Industry Development Institute RS-2025-25406739National Research Foundation of Korea RS-2023-00270936National Research Foundation of Korea RS-2024-00352590
6 · The paper itself

Abstract

CRISPR-Cas systems have transformed viral genetics by enabling precise and efficient manipulation of large DNA virus genomes. This review provides a practical framework for applying CRISPR technology to herpesviruses and other large DNA viruses as an alternative and complement to traditional BAC recombination. Key considerations include nuclease choice; sgRNA design that minimizes cut-to-edit distance and prevents re-cutting; donor template configuration and homology arm length; and synchronized delivery of Cas complexes and donor DNA. Strategies to promote HDR efficiency, such as the use of small-molecule modulators, are also summarized. In addition, practical workflows for clone selection, genotypic validation, and phenotypic confirmation are summarized. Case studies in herpes simplex virus type 1 and human cytomegalovirus illustrate how optimized CRISPR designs achieve reproducible, scarless knock-ins and conditional gene manipulation at essential loci without complementing cell lines. Together, these approaches establish CRISPR as a flexible, scalable platform for functional genomics, antiviral target discovery, and translational virology, enabling direct editing of clinical isolates previously inaccessible with bacterial artificial chromosome-based methods.

Indexed as

CRISPR-Cas SystemsGene EditingGenome, ViralClustered Regularly Interspaced Short Palindromic RepeatsCytomegalovirusHerpesviridaeHerpesvirus 1, HumanHumansCRISPR-Cas genome editingherpesvirus geneticshomology-directed repair

Identifiers

PMID41705810
PMCPMC13011484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.